Exhibit 99.2

ACTengine® IMA203 TCR - T Targeting PRAME in PD1 Refractory Metastatic Melanoma - Phase 1b Dose Expansion Clinical Data Update October 10, 2024 Oral presentation by Martin Wermke at the Society of Melanoma Research Congress on October 11, 2024 Data cut - off Aug 23, 2024 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution.

Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation . Forward - Looking Statements . Certain statements in this presentation may be considered forward - looking statements . Forward - looking statements generally relate to future events or the Company’s future financial or operating performance . For example, statements concerning timing of data read - outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration - enabling), the timing of IND or CTA filing for pre - clinical stage product candidates, the timing of BLA filings for clinical stage product candidates, estimated market opportunities of product candidates, manufacturing timetables, capacity and success rates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward - looking statements . In some cases, you can identify forward - looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology . Such forward - looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements . These forward - looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain . New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties . Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20 - F and other filings with the Securities and Exchange Commission (SEC) . Nothing in this presentation should be regarded as a representation by any person that the forward - looking statements set forth herein will be achieved or that any of the contemplated results of such forward - looking statements will be achieved . You should not place undue reliance on forward - looking statements, which speak only as of the date they are made . The Company undertakes no duty to update these forward - looking statements . No Offer or Solicitation . This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction . No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933 , as amended, or in an offering exempt from registration . Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research . In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions . Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source . All the scientific and clinical data presented within this presentation are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification . 2

PRAME – A Widely Expressed Cancer Testis Antigen 3 100 100 µm 81 90 % PRAME+ cells PRAME RNA Detection in Melanoma Samples (ISH) % PRAME Positive Patients in Selected Indications Uterine Carcinosarcoma Sarcoma Subtypes Uterine Carcinoma Cut. Melanoma Uveal Melanoma 1 Ovarian Carcinoma Squamous NSCLC T NBC Small Cell Lung Cancer 100% 0% 100% 95% up to 100% 95% 90 % 85% 70% 60% 45% Target prevalence based on TCGA (SCLC: in - house) RNAseq data combined with proprietary mass spec - guided RNA expression threshold; 1 Uveal melanoma target prevalence based on IMADetect qPCR testing of screening biopsies from 61 trial patients. ISH: in - situ hybridization Data cut - off Aug 23, 2024

ACTengine® IMA203 TCR - T Monotherapy – Patient Flow 4 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Low dose IL - 2 ** Safety and efficacy monitoring for 12 months Leukapheresis x x Expression Antigen 1 2 3 * 30 mg/m 2 Fludarabine and 500 mg/m 2 Cyclophosphamide for 4 days; ** 1m IU daily days 1 - 5 and twice daily days 6 - 10 Short process time of 14 days 7 - day manufacturing process applying CD8/CD4 T cell selection 7 - day QC release testing 95% (138/146) Cut. Melanoma 89% (54/61) Uveal Melanoma 93% (14/15) Uterine Carcinoma 81% (48/59) Ovarian Carcinoma Target Profiling IMADetect® mRNA assay using Immatics’ MS - guided threshold; Biopsy or archived tissue Patient screening data from Immatics’ clinical trials: Data cut - off Aug 23, 2024

ACTengine® IMA203 TCR - T Trial in Melanoma Heavily Pretreated Patient Population 5 Data cut - off Aug 23, 2024 1 See patient flow in appendix. 2 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints, see appendix; RP2D: recommended phase 2 dose; CPI: Checkpoint inhibitors; EC1: 0.06 - 0.12x10 9 TCR - T cells/m 2 BSA; DL3: 0.2 - 0.48x10 9 TCR - T cells/m 2 BSA, DL4: 0.2 - 1.2x10 9 TCR - T cells/m 2 BSA, DL5: 1.201 - 4.7x10 9 TCR - T cells/m 2 BSA Melanoma Efficacy Population 2 Melanoma Dose Escalation Population Total Safety P o p ul a t i o n 1 Melanoma (Phase 1b, at RP2D) Mela n o m a (Phase 1a) All Comers (Phase 1a and Phase 1b) N= 2 8 N= 13 N= 12 N= 1 N=2 Total Cutaneous melanoma Uveal melanoma Melanoma of unknown primary Mucosal melanoma N= 1 1 N=8 N=2 N=1 Total Cutaneous melanoma Uveal melanoma Mucosal melanoma N = 7 0 N= 41 N= 29 Total M el an om a Other Number of patients 2 (0, 6) 1* (0, 4) 4 (2, 7) 2 (1, 4) 3 (0, 9) 2 (0, 4) Prior lines of systemic treatment (median, min, max) Thereof CPI (melanoma only) (median, min, max) 60 .7 81 .8 64.3 LDH at baseline >1 x ULN [% of patients] 107.5 (15.0, 309.8) 117.5 (37.0, 211.0) 117.8 (15.0, 309.8) Baseline tumor burden Median Target lesion sum of diameter [mm] (min, max) 82 .1 63 .6 65.7 Liver/brain lesions at baseline [% of patients] DL4/5 EC1/DL3/4 DL1 - 5 Dose level 4.1 (1.3, 10.2) 0.586 (0.10, 2.09) 2.09 (0.08, 10.2) Total infused dose TCR - T cells [x10 9 ] Melanoma Efficacy Population 2 (N=28) Melanoma Patients in Phase 1b Dose Expansion RP2D defined at 1 - 10x10 9 TCR - T cells (DL4/5) Total Safety Population 1 (N=70) Phase 1a Dose Escalation Dose Level 1 - 4 (total safety pop. N=28) Phase 1b Dose Expansion Dose Level 4/5 (total safety pop. N=42)

6 Data cut - off Aug 23, 2024 • Most frequent adverse events were expected cytopenias (Grade 1 - 4) associated with lymphodepletion in all patients • Mostly mild to moderate cytokine release syndrome (CRS) • 37% (26/70) Grade 1 • 46% (32/70) Grade 2 • 11% (8/70) Grade 3 2 • Infrequent ICANS (6% Grade 1, 4% Grade 2, 4% Grade 3) • No IMA203 - related deaths • Full IMA203 monotherapy tolerability profile is available in appendix • Tolerability in the melanoma subset is generally consistent with the full IMA203 monotherapy tolerability profile 1 See patient flow in appendix; 2 One grade 3 CRS only after exploratory second infusion; CRS and ICANS graded by CARTOX criteria (Neelapu et al ., 2019); ICANS: Immune Effector Cell - Associated Neurotoxicity Syndrome. Most Frequent Adverse Events of IMA203 Across All Dose Levels in Phase 1a/b N=70 Patients in Total Safety Population 1 Favorable tolerability profile for IMA203 monotherapy at recommended phase 2 dose (1x10 9 to 10x10 9 TCR - T cells)

Best Overall Response for IMA203 in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28 # ) 7 Data cut - off Aug 23, 2024 ongoi n g # First tumor assessment post infusion pending for two melanoma patients at data - cut; * Maximum change of target lesions and RECIST1.1 response at different timepoints. **Tumor shrinkage of target lesions; 1 Patient A - DL5 - 23 is off study at data cut - off; 2 Patient out of study due to PD (external assessment); Initial ORR: Objective response rate according to RECIST 1.1 at any post infusion scan; Confirmed ORR (cORR): Confirmed objective response rate according to RECIST 1.1 for patients with at least two available post infusion scans or patients with PD at any prior timepoint, patients with ongoing unconfirmed PR not included in cORR calculation; Duration of response (DOR) in confirmed responders is defined as time from first documented response until disease progression/death. Patients with ongoing response will be censored at date of data cut - off. Median DOR is analyzed by using the Kaplan - Meier method; Overall survival (OS) and progression - free survival (PFS) censored at data - cut; BL: Baseline PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response; DCR: Disease control rate, mFU: median follow - up 54% (14/26) cORR 12.1 months (4.2, 25.5+ months) 9.3 months median DOR (min, max) mFU 7/14 confirmed responses ongoing 6.0 months (0.3+, 26.8+ months) median PFS (min, max) Not reached (0.3+, 26.8+ months) 8.6 months median OS (min, max) mFU 62% (16/26) O R R 88% (23/26) Tumor shrinkage ** 92% (24/26) DCR (at week 6)

Response Over Time of IMA203 in Melanoma Durable Responses 2 Years+ after Treatment in Heavily Pretreated Patients in Phase 1b (N=28 # ) 8 Ongoing Scans at approximately week 6, month 3 and then every 3 months Data cut - off Aug 23, 2024 # First tumor assessment post infusion pending for two melanoma patients at data - cut; *Tumor shrinkage of target lesions; 1 Patient out of study due to PD (external assessment) 2 Patient A - DL5 - 23 is off study at data cut - off; Initial ORR: Objective response rate according to RECIST 1.1 at any post infusion scan; Confirmed ORR (cORR): Confirmed objective response rate according to RECIST 1.1 for patients with at least two available post infusion scans or patients with PD at any prior timepoint, patients with ongoing unconfirmed PR not included in cORR calculation; Duration of response (DOR) in confirmed responders is defined as time from first documented response until disease progression/death. Patients with ongoing response will be censored at date of data cut - off. Median DOR is analyzed by using the Kaplan - Meier method; Overall survival (OS) and progression - free surviv al (PFS) censored at data - cut; BL: Baseline PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response; DCR: Disease control rate, mFU: median follow - up 54% (14/26) cORR 12.1 months (4.2, 25.5+ months) 9.3 months median DOR (min, max) mFU 7/14 confirmed responses ongoing 6.0 months (0.3+, 26.8+ months) median PFS (min, max) Not reached (0.3+, 26.8+ months) 8.6 months median OS (min, max) mFU 62% (16/26) O R R 88% (23/26) Tumor shrinkage ** 92% (24/26) DCR (at week 6)

 

Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS Not Reached in Melanoma Efficacy Population 9 Progression Free Survival Data cut - off Aug 23, 2024 Overall Survival Overall survival (OS) and progression - free survival (PFS) censored at data - cut; * These data are derived from different clinical trials at different points in time with differences in trial design and patient populations. As a result, cross - trial comparisons cannot be made, and no head - to - head clinical trials have been conducted. mPFS N 2.6 months 11 Dose Escalation 6.0 months 28 Dose Expansion mOS N 6.3 months 11 Dose Escalation Not reached 28 Dose Expansion Log - rank test: p=<0.0001 Log - rank test: p=0.0003 • Significant shift in PFS and OS between melanoma patients treated during the dose escalation and dose expansion phase • PFS in dose escalation is comparable to reported data in 2L+ cut. melanoma population* • OS in dose escalation is shorter than reported OS for 2L+ cut. melanoma population* • All patients in the dose escalation group died and 20/26 patients are alive in dose expansion

IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in 2L+ Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies 2L+ melanoma patient population N Phase Drug Product not reached 6.0 4% n=0, 18% n=1, 32% n=2, 29% n=3:, 4% n=4, 11% n=5, 4% n=6 86% received prior CPI (median of 1 prior line of CPI in overall population, median of 2 prior lines of CPI in cut. melanoma) Median of 2 prior lines, median of 2 prior lines in cut. melanoma 46% cutaneous 43% uveal 11% other 28 1b (Dose Expansion) IMA203 in Melanoma 6.3 2.6 0% n=1, 27% n=2, 73% n>2 prior lines 100% received prior CPI (median of 2 prior lines of CPI, median of 2.5 prior lines of CPI in cut. melanoma) Median of 4 prior lines, median of 4.5 prior lines in cut. melanoma 73% cutaneous 18% uveal 9% other 11 1a (Dose Escalation) IMA203 in Melanoma 5.3 2.5 0% n=1, 16% n=2, 84% n>2 prior lines 100% received prior CPI (median 3 prior lines of CPI) Median of 4 prior lines, median of 4.5 prior lines in cut. melanoma 63% cutaneous 11% uveal 26% other 19 1a (Dose Escalation) IMA201/202/203 combined in Melanoma 13.9 4.1 median of 3 prior lines (min/max: 1/9) 100% received prior CPI 54% cutaneous 0% uveal 45% other 153 2 Lifileucel (C - 144 - 01, Cohort 2+4) 1 11.6 2.9 57% n=1, 27% n=2, 12% n>2 prior lines 99% received prior CPI 85% cutaneous 0% uveal 15% other 238 3 Tilsotolimod + Ipilimumab (ILLUMINATE - 301) 2 14.7 2.1 46% n=1, 35% n=2, 19% n≥3 prior lines 99% received prior CPI 68% cutaneous 0% uveal 32% other 354 1/2 Nivolumab + Relatlimab (RELATIVITY - 020, D1 Cohort) 3 Data cut - off Aug 23, 2024 10 1 Chesney et al., 2022; 2 Diab et al., 2024; 3 Ascierto et al., 2023. These data are derived from different clinical trials at different points in time with differences in trial design and patient populations. As a result, cross - trial comparisons cannot be made, and no head - to - head clinical trials have been conducted.

Enhanced PFS in Phase 1b Melanoma Patients with Deep Responses N=26 # 11 • Approx. half of all patients have a deep response (>50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase) still observe a more than 2x longer mPFS as compared to patients treated in dose escalation with suboptimal doses Data cut - off Aug 23, 2024 mPFS N 2.6 months 11 Dose Escalation IMA203 5.7 months 14* Dose Expansion IMA203 <50% tumor size reduction (including tumor size increase) 13.4 months 12 Dose Expansion IMA203 > 50% tumor size reduction # Excluding two patients that were infused but did not have their first tumor assessment post baseline at data - cut; *Includes one patient with ongoing SD 4.4 months after infusion with tumor reduction <50% Log - rank: p=0.0033

0 5 î 10 5 1 î 10 6 1.5 î 10 6 2 î 10 6 2.5 î 10 6 Cmax (vector copies/μg gDNA) 4 6 8 10 Infused Total (CD8 + Dex + ) IMA203 T cell dose (x10 9 ) 2 1 0 Dose Response Relationship IMA203 T Cell Dose is Associated with Clinical Activity and IMA203 T Cell Exposure (N=65 out of 68*) 12 RP2D cPR (n=23) PR or SD or PD (n=42) IMA203 T Cell Dose is Associated with Clinical Activity IMA203 T Cell Dose Correlates with T Cell Exposure 1 Mann - Whitney U test, 2 Spearman Correlation; * no data available yet for patients recently treated; PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response; , RP2D: recommended phase 2 dose p = 0.0180 1 r=0.8396 p=1.646e - 018 2 Data cut - off Aug 23, 2024

Exposure Response Relationship IMA203 T Cell Persistence Over Time and T Cell Exposure is Associated with Clinical Response 13 Rapid T cell engraftment (C max ) in all patients with over two years of persistence Higher C max and persistence in patients treated at higher doses in dose expansion versus dose escalation cPR P R / S D / P D 1 Mann - Whitney U test; * no data available yet for patients recently treated; PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response, AUC: Area under curve Data cut - off Aug 23, 2024 1 1 î 10 2 1 î 10 3 1 î 10 4 1 î 10 5 1 î 10 6 1 î 10 7 2 8 1 4 2 0 2 6 2 8 4 8 6 8 8 8 200 400 600 800 Persistence Overtime Days post infusion Vector copies/ ug gDNA N = 2 7 N = 3 8 Persistence over Time Dose Escalation Dose Expansion N=65 out of 68* N=65 out of 68* IMA203 T cell exposure (C max & AUC (0 - 28d) ) is associated with clinical responses 1 î 10 7 2 î 10 7 3 î 10 7 AUC (0 - 28d) of TCR T Cell Concentration in Blood (vector copies/μg DNA) p = 0.0517 1 1 î 10 3 1 î 10 4 1 î 10 5 1 î 10 6 1 î 10 7 2 8 1 4 2 0 2 6 2 8 4 8 6 8 8 8 200 400 600 800 Days post infusion Vector copies/ ug gDNA

Patient Case A - DL4 - 03 : Cutaneous Melanoma 14 Images courtesy of treating physician (Dr. Martin Wermke, University of Dresden) PET - based Complete Response 15 Months Post Infusion and Ongoing Response at 24 Months 51 - year - old male patient with complete remission according to PET imaging after 15 months and ongoing beyond two years post infusion at data cut • 5 prior systemic treatment lines: • Dabrafenib + Trametinib • Pembrolizumab • Dabrafenib + Trametinib + Vemurafenib + Cobimetinib • Tebentafusp • Encorafenib + Binimetinib • 13 years of cancer history • 23 mm target lesion in cervical lymph node and non - target lesions in pelvic bone and lung • Patient received ~1.3x10 9 IMA203 TCR - T cells • Ongoing PR at 24 months post infusion with - 78.3% reduction according to RECIST1.1 • Metabolic complete response reported based on investigator - initiated PET imaging at baseline and month 15 post infusion Follow - up Month 15 Follow - up Month 27 (Post data cut - off) Baseline Follow - up Month 12 Data cut - off Aug 23, 2024

SUPRAME: Registration - enabling Randomized Phase 3 Trial Trial Design Following Recent Type D Meeting with FDA and SA Meeting with PEI 1 15 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=1 8 0 Endpoints • Primary Endpoint • PFS • Secondary Endpoints • Safety • ORR + DOR • No OS detriment • Patient - reported outcomes (EORTC QLQ - C30, EQ - 5D - 5L) mPFS: median progression - free survival, ORR: objective response rate; 1 Scientific Advice Meeting with Paul - Ehrlich - Institute, the German regulatory authority Randomization 1 : 1 Next Steps • SUPRAME Phase 3 trial is projected to commence in December 2024 • Pre - specified interim analysis planned after approx. 200 patients enrolled • Full enrollment anticipated by late 2026 Patient Population: unresectable or metastatic melanoma post - treatment with a checkpoint inhibitor (2L+) N=360

ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME in Melanoma Summary of Clinical Data Tolerability PFS & OS Biological Data Broad Reach Favorable tolerability profile: mostly mild to moderate CRS; infrequent ICANS (5.7% Gr1, 4.3% Gr2, 4.3% Gr3); no treatment related deaths Anti - Tumor Activity & Durability 54% (14/26) cORR and 92% (24/26) DCR; 12.1 months mDOR and ongoing responses for over two years PFS of 6 months and OS not reached (mFU 8.6 months) T cell dose and exposure are significantly associated with clinical response FDA RMAT designation received in multiple PRAME expressing cancers including cutaneous and uveal melanoma Data cut - off Aug 23, 2024 16 SUPRAME Phase 3 trial is projected to commence in December 2024

17 We are Immensely Grateful to the Patients, Their Families … University Hospital Dresden University Hospital Bonn University Hospital Würzburg University Hospital Hamburg Ge r ma n y Dr. M. Wermke Charité Berlin University Hospital Heidelberg University Medicine Mainz Columbia U n iv e rsity University of Pittsburgh MD Anderson Cancer Center United States University of Miami Health System Fox Chase Cancer Center … and the Investigators at the Clinical Sites Sponsor: Immatics

A p pen d ix 18

Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b All ≥Grade 3 Adverse Events (N=70 1 ) TEAEs by maximum severity for all patients in Phase 1a and Phase 1b (N=70 1 ) Data cut - off Aug 23, 2024 19 ≥ Grade 3 Adverse event ( System organ class , Preferred term) % No. 100.0 70 Patients with any adverse event 12.9 9 Adverse Events of Special Interest 11.4 8 Cytokine release syndrome 4.3 3 ICANS 2 100.0 70 Blood and lymphatic system disorders 88.6 62 Neutropenia 55.7 39 Lymphopenia 54.3 38 Leukopenia 51.4 36 Anaemia 34.3 24 Thrombocytopenia 2.9 2 Febrile neutropenia 1.4 1 Cytopenia 1.4 1 Leukocytosis 14.3 10 Infections and infestations 2.9 2 Urinary tract infection 1.4 1 Appendicitis 1.4 1 COVID - 19 1.4 1 Cytomegalovirus infection reactivation 1.4 1 Enterococcal infection 1.4 1 Human herpesvirus 6 encephalitis 1.4 1 Infection 1.4 1 Orchitis 1.4 1 Sepsis 3,4 1.4 1 Septic shock 3 14.3 10 Investigations 8.6 6 Alanine aminotransferase increased 7.1 5 Aspartate aminotransferase increased 2.9 2 Blood creatinine increased 1.4 1 Blood alkaline phosphatase increased 1.4 1 Blood bilirubin increased 1.4 1 Blood fibrinogen decreased 1.4 1 Lymphocyte count increased 14.3 10 Respiratory, thoracic and mediastinal disorders 5.7 4 Hypoxia 2.9 2 Pleural effusion 1.4 1 Bronchial obstruction 1.4 1 Dyspnoea 1.4 1 Epistaxis 1.4 1 Laryngeal inflammation 1.4 1 Respiratory failure All treatment - emergent adverse events (TEAEs) with ≥ Grade 3 regardless of relatedness to study treatment . Adverse events were coded using the Medical Dictionary for Regulatory Activities . Grades were determined according to National Cancer Institute Common Terminology Criteria of Adverse Events, version 5 . 0 . Grades for Cytokine release syndrome and ICANS were determined according to CARTOX criteria (Neelapu et al . , 2019 ) . Patients are counted only once per adverse event and severity classification . Based on interim data extracted from open clinical database ( 23 - Aug - 2024 ) ; 1 Two patients with disease progression after first IMA 203 infusion received exploratory second IMA 203 infusion . They had these ≥ Grade 3 TEAEs only after second infusion, which are included in the table : First patient : Abdominal pain, Cytokine release syndrome, Diarrhoea, Hypokalaemia, Proteinuria ; Second patient : Humerus fracture, Muscle spasms, Neutropenia, Thrombocytopenia ; 2 ICANS : Immune effector cell - associated neurotoxicity syndrome ; 3 Fatal Adverse events were not considered related to any study drug ; 4 Patient died from sepsis of unknown origin and did not receive IMA 203 TCR - T cells ; 5 DLT : Dose limiting toxicity in phase 1 a at DL 2 reported on March 17 , 2021 . table continued… 10.0 7 Metabolism and nutrition disorders 4.3 3 Hypokalaemia 4.3 3 Hyponatraemia 2.9 2 Hypophosphataemia 1.4 1 Dehydration 1.4 1 Failure to thrive 10.0 7 Vascular disorders 8.6 6 Hypertension 1.4 1 Hypotension 8.6 6 Renal and urinary disorders 5.7 4 Acute kidney injury 1.4 1 Nephritis 1.4 1 Proteinuria 7.1 5 Gastrointestinal disorders 4.3 3 Abdominal pain 1.4 1 Diarrhoea 1.4 1 Ileus 1.4 1 Vomiting 5.7 4 General disorders and administration site conditions 1.4 1 Fatigue 1.4 1 General physical health deterioration 3 1.4 1 Pyrexia 1.4 1 Swelling face 5.7 4 Skin and subcutaneous tissue disorders 4.3 3 Rash maculo - papular 1.4 1 Eczema 4.3 3 Cardiac disorders 4.3 3 Atrial fibrillation 5 2.9 2 Eye disorders 1.4 1 Periorbital oedema 1.4 1 Ulcerative keratitis 2.9 2 Injury, poisoning and procedural complications 1.4 1 Humerus fracture 1.4 1 Infusion related reaction 2.9 2 Musculoskeletal and connective tissue disorders 1.4 1 Back pain 1.4 1 Muscle spasms Adverse event ( System organ class , Preferred term) ≥ Grade 3 No. % table continued… 2.9 2 Nervous system disorders 1.4 1 Headache 1.4 1 Posterior reversible encephalopathy syndrome 1.4 1 Endocrine disorders 1.4 1 Inappropriate antidiuretic hormone secretion 1.4 1 Hepatobiliary disorders 1.4 1 Cholangitis 1.4 1 Immune system disorders 1.4 1 Haemophagocytic lymphohistiocytosis 1.4 1 Reproductive system and breast disorders 1.4 1 Vaginal haemorrhage Adverse event ( System organ class , Preferred term) ≥ Grade 3 No. %

IMA203 Phase 1 Patient Population Flow Chart 20 Data cut - off Aug 23, 2024 * Melanoma efficacy population excludes 5 patients treated at DL4 in Phase 1a of the trial as reported in the May 2024 update, based on different manufacturing version used that affects the T cell product (see slide 22); Current manufacturing version: T cell enrichment process using monocyte depletion (negative selection) or CD8/CD4 positive selection; prior manufacturing version: manufacturing process without specific T cell enrichment; 1 Except one DL3 patient with current manufacturing version. Total Safety Population (N=70 enrolled patients) N=1 patient in Phase 1a started lymphodepletion but did not receive IMA203 N=1 patient had lymphodepletion but IMA203 infusion was scheduled after data cut - off N=68 patients treated with IMA203 N=27 patients in Phase 1a Dose Escalation (DL1 - 4) N=11 melanoma patients N=16 non - melanoma patients N=41 patients in Phase 1b Dose Expansion (DL4/5, RP2D) Melanoma Efficacy Population * (n=28) thereof 2 patients without post - baseline scan N=13 non - melanoma patients N=6 melanoma patients (DL1 - 3) N=5 melanoma patients (DL4) Previous manufacturing version Previous manufacturing version 1 Current manufacturing version Current manufacturing version Thereof n=65 evaluable for T cell exposure analysis Thereof n=38 evaluable for T cell persistence analysis

Baseline Characteristics of Melanoma Patients in Phase 1a and Phase 1b Focus on Cutaneous and Uveal Melanoma Melanoma Efficacy Population 1 Melanoma Dose Escalation Population Uveal Melanoma (N=12) Cutaneous Melanoma (N=13) Uveal Melanoma (N=2) Cutaneous Melanoma (N=8) Indication 2.5 (0, 6) 1 (0, 4) 2 (1, 5) 2 (1, 3) 2 (2, 2) 1 (1,1) 4.5 (2, 7) 2.5 (2,4) Prior lines of systemic treatment (median, min, max) Thereof CPI (melanoma only) (median, min, max) 58.3 69.2 100.0 75.0 LDH at baseline >1 x ULN [% of patients] 107.5 (38.6, 210.0) 123.0 (15.0, 309.8) 153,5 (109.9, 198.0) 106.3 (37.0, 211.0) Baseline tumor burden Median Target lesion sum of diameter [mm] (min, max) 91.7 69.2 100.0 50.0 Liver/brain lesions at baseline [% of patients] DL4/DL5 DL4/DL5 EC1, DL3 EC1/DL4 Dose level 4.33 (1.62, 8.43) 4.04 (1.3, 10.2) 0.417 (0.248, 0.586) 1.115 (0.099, 2.09) Total infused dose TCR - T cells [x10 9 ] Data cut - off Aug 23, 2024 21 1 All infused melanoma patients in Ph1b dose expansion; CPI: Checkpoint inhibitors; EC1: 0.06 - 0.12x10 9 TCR - T cells/m 2 BSA; DL3: 0.2 - 0.48x10 9 TCR - T cells/m 2 BSA ; DL4: 0.2 - 1.2x10 9 TCR - T cells/m 2 BSA, DL5: 1.201 - 4.7x10 9 TCR - T cells/m 2 BSA Cutaneous melanoma patients in Phase 1b had similar prior CPI exposure, higher tumor burden and higher incidence of liver/brain lesions compared to Phase 1a

 

Favorable TCR - T Product Characteristics and High TCR - T Levels in Patients Manufacturing Improvements Implemented in Phase 1b Enhance Key Features of the Cell Product 22 Robust TCR - T product features Increased peak IMA203 T cell levels in patients DL4 only, normalized to cell dose Data cut - off Aug 23, 2023 1 Current: T cell enrichment process using monocyte depletion (negative selection) or CD8/CD4 positive selection; prior: manufacturing process without specific T cell enrichment; 2 one patient started lymphodepletion but did not receive IMA203 T cells; 3 no data available yet for patients recently treated * • Manufacturing improvements including T cell enrichment process (i.e. removal of monocyte fraction or CD8/CD8 selection) implemented in Phase 1b lead to improved TCR - T product features and increased TCR - T levels in patients • The efficacy - evaluable population in this analysis (data cut - off Aug 23, 2024) focuses on this patient population only and reflects the expected population and product to be evaluated in the pivotal trial 0 2 0 4 0 6 0 8 0 100 %TCR+ (of CD3+CD8+ cells) P < 0.0001 0 5 î 10 9 1 î 10 10 1.5 î 10 10 2 î 10 10 Total TCR+ T Cells P < 0.0001 GEN1 prior (n=27) I M A 203 I M A 203 GEN1 cu rr ent (n=43) 0 2 î 10 5 4 î 10 5 6 î 10 5 8 î 10 5 Vector copies/μg gDNA P = 0.0003 GEN 1 p r ior (n=7) IMA203 IMA203 GEN1 cu rr ent (n=9) Man u f actur i ng proces s 1 2 3

T Cell Selection Results in ‘Younger’ Phenotype of the TCR - T Product Consequently, Terminally Differentiated T Cells are also Decreased 23 L = Low enrichment (n=7, prior manufacturing version) M = Medium enrichment (n=37, current manufacturing version) H = High enrichment (n=38, current manufacturing version) Presented at the Process Development Summit 2024; L: No specific T cell enrichment; M: monocyte depletion (negative selection); H: CD4/CD8 T cell selection (positive selection); Results are represented as separated scatter with median; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = not significant by a two - way ANOVA with Tukey’s Multiple Comparisons. L M H L M H L M H L M H 0 4 0 2 0 6 0 8 0 1 0 0 %Positive (Gated off CD8+ ) T na i ve T - cm T - em T - eff n s ٓٓ ٓٓٓٓ n s n s n s n s ٓٓٓٓ ٓٓٓٓ n s n s n s

Melanoma Patients Treated with IMA203 in Phase 1b Dose Expansion Efficacy - evaluable Population (n=28*) Reason for Progression Comment BOR (Max % change of target lesions) B OR Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior treatment lines Indication Patient ID Ongoing response at 26.8 months PFS - 83.9 cPR 4.16 ARRY614 + Nivolumab 1 Uveal Melanoma A - DL5 - 01 Ongoing response at 26.5 months PFS - 78.3 cPR 1.30 Dabrafenib + Trametinib Pembrolizumab Dabrafenib + Trametinib + Vemurafenib + Cobimetinib T eben taf us p Encorafenib + Binimetinib 5 Cut. Melanoma A - DL4 - 03 Ongoing response at 12.0 months PFS - 56.3 cPR 9.80 Nivolumab Pembrolizumab Ipilimumab + Nivolumab 3 Cut. Melanoma A - DL5 - 13 Ongoing response at 8.6 months PFS - 77.9 cPR 7.19 Valproic acid + Sunitinib Tebentafusp 2 Uveal Melanoma A - DL5 - 21 Ongoing response at 7.3 months PFS - 60.4 cPR 8.14 Melphalan Tebentafusp 2 Uveal Melanoma A - DL5 - 26 Ongoing response at 7.0 months PFS - 66.7 cPR 10.20 Relatlimab + Nivolumab 1 Cut. Melanoma A - DL5 - 27 Ongoing stable disease at 4.2 months PFS - 4.1 SD 3.68 Ipilimumab + Nivolumab AB122 + AB154 Encorafenib + Binimetinib 3 Cut. Melanoma A - DL5 - 31 Ongoing response at 6 months PFS, patient off study at data - cut due to investigator decision (radiation of one target lesion) - 44.8 cPR 6.94 Ipilimumab + Nivolumab Encorafenib + Binimetinib Relatlimab + Nivolumab 3 Cut. Melanoma A - DL5 - 23 Progression as determined by external assessment Response until 13.4 months PFS - 65.1 cPR 5.12 Interferon Pembrolizumab Ipilimumab + Nivolumab 3 Cut. Melanoma A - DL5 - 03 Non - target lesion progression Response until 8.5 months PFS - 50.9 cPR 5.42 Pembrolizumab Clinical trial intrahepatic PV10 Ipilimumab + Nivolumab Clinical trial Anti - CTLA - 4 NF AB + XRT Clinical trial foghorn FHD - 286 Pembrolizumab 6 Uveal Melanoma A - DL5 - 19 Non - target lesion progression and new lesions Response until 6.2 months PFS - 4 8.1 cPR 2.89 NOX66 - 005 Idronoxil with radiotherapy IDE196 + Crizotinib LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide 3 Uveal Melanoma A - DL5 - 24 Target lesion and non - target lesion progression Response until 6.0 months PFS - 57.1 cPR 7.94 Nivolumab Ipilimumab + Nivolumab 2 Mucosal Melanoma A - DL5 - 29 Target lesion progression Response until 5.8 months PFS - 40.8 cPR 2.68 SEAGEN CD40 Agonist 1 Uveal Melanoma A - DL5 - 10 New lesions Response until 5.7 months PFS - 65.9 cPR 1.55 Nivolumab + Ipilimumab Brektovi + Mektovi + Nivolumab + Relatlimab 2 Cut. Melanoma A - DL4 - 07 New lesions Response until 5.6 months PFS - 58.8 cPR 3.02 Pembrolizumab 1 Cut. Melanoma A - DL5 - 15 * First tumor assessment post infusion pending for two melanoma patients at data - cut; 1 Transduced viable CD8 T cells; BOR: Best overall response; DL: Dose level; PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response; PFS: Progression - free survival (censored at data - cut) Data cut - off Aug 23, 2024 24

Reason for Progression Comment BOR (Max % change of target lesions) BOR Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior treatment lines Indication Patient ID New lesions Disease stabilization until 2.7 months post infusion, unconfirmed response from 2.7 until 5.5 months PFS - 59.3 PR 6.31 I pili m u ma b+Ni v o l u mab Tafinlar + Mekinist 2 Cut. Melanoma A - DL5 - 22 Target lesion progression Unconfirmed response until 2.8 months PFS - 36.9 PR 3.33 Ipilimumab + Nivolumab Avapritinib Opdualag 3 Mucosal Melanoma A - DL5 - 28 Non - target lesion progression Disease stabilization until 8.6 months PFS - 17.6 SD 8.43 Ipilimumab + Pembrolizumab Tebentafusp Ipilimumab + Nivolumab IDE196 + Binimetinib FHD - 286 5 Uveal Melanoma A - DL5 - 20 New lesion Disease stabilization until 6.1 months PFS - 18.6 SD 4.04 Ipilimumab + Nivolumab+Tociliziumab Nivolumab + Relatlimab + Tocilizumab + Ipilimumab 2 Cut. Melanoma A - DL5 - 17 New lesions, target lesion progression Disease stabilization until 5.9 months PFS 11.4 SD 1.63 Nivolumab Nivolumab + Ipilimumab Dabrafenib + Trametinib Nivolumab 4 Cut. Melanoma A - DL4 - 05 Non - target lesion progression and a new lesion Disease stabilization until 5.7 months PFS 0.0 SD 1.73 Ipilimumab + Nivolumab 1 Melanoma (Unk. Primary) A - DL4 - 04 New lesion Disease stabilization until 5.5 months PFS - 25.4 SD 5.71 Tebentafusp Ipilimumab + Nivolumab 2 Uveal Melanoma A - DL5 - 18 Target and non - target lesion progression, new lesions Disease stabilization until 3.5 months PFS - 22.6 SD 4.50 Tyrosinase peptides Nivolumab + Ipilimumab + Denosumab Tebentafusp 3 Uveal Melanoma A - DL5 - 12 Non - target lesion progression, new lesions Disease stabilization until 2.7 months PFS 4.6 SD 5.14 Ipilimumab + Nivolumab Axitinib + Nivolumab 2 Cut. Melanoma A - DL5 - 25 New lesion Progressive disease at 1.4 months PFS - 6.3 PD 2.56 NA 0 Uveal Melanoma A - DL4 - 06 New lesions Progressive disease at 1.4 months PFS - 41.5 PD 2.34 Nivolumab Encorafenib + Binimetinib 2 Cut. Melanoma A - DL5 - 14 First scan post infusion pending at data cut - off N/A N/A 3.18 Ipilimumab + Nivolumab Tebentafusp Ipilimumab + Nivolumab DYP - 688 Ipilimumab + Nivolumab 5 Uveal Melanoma A - DL5 - 32 First scan post infusion pending at data cut - off N/A N/A 1.62 Ipilimumab + Nivolumab Darovasertib Tebentafusp 3 Uveal Melanoma AA - 1 Data cut - off Aug 23, 2024 25 Melanoma Patients Treated with IMA203 in Phase 1b Dose Expansion (cont.) Efficacy - evaluable Population (n=28*) *First tumor assessment post infusion pending for two melanoma patients at data - cut; 1 Transduced viable CD8 T cells; BOR: Best overall response; DL: Dose level; PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response; PFS: Progression - free survival (censored at data - cut)

 

Patient Case A - DL5 - 01: Uveal Melanoma Long - term Responder Ongoing at 26+ Months B a seline Follow - up Month 1 - 51% PR Follow - up Month 26 - 83% PR 71 - year - old male patient with ongoing shrinkage of liver lesion 26+ months post treatment • 1 prior line of systemic treatment: ARRY614 + Nivolumab • 6 years of cancer history • 99.2 mm target lesion sum • Patient received ~4x10 9 IMA203 TCR - T cells RECIST Change from Baseline (%) Overall RECIST1.1 assessment CT scans courtesy of treating physician (Dr. Jason Luke, University of Pittsburgh) Data cut - off Aug 23, 2024

 

Patient Case A - DL5 - 033: Cutaneous Melanoma Changes of a Melanoma Lesion of the Skin within 8 Days (Post Data Cut - off) Data cut Aug 23, 2024; Patient was treated post data cut - off date (Aug 26, 2024); Images courtesy of treating physician (Dr. Jason Luke, University of Pittsburgh) Follow - up Day 15 Follow - up Day 8 Base l i n e 61 - year - old male patient demonstrated changes of a melanoma lesion of the skin 8 days post IMA203 infusion • 4 prior systemic treatment lines: 3 lines of CPI, 1 line of Brenetafusp (PRAME) • 8 years of cancer history • 118 mm target lesion sum • Patient received ~10x10 9 IMA203 TCR - T cells

Deli v ering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. www.immatics.com